Company intelligence / Profile preview

20BLOC

Thousand Oaks, California, United States20bloc.com ↗

Ownership: Private
Development stage: Preclinical

Overview

20BLOC is developing a novel hemoglobin-based oxygen carrier designed to replace or supplement blood by delivering oxygen to tissues. The product is acellular, universally compatible with all blood types, stable at room temperature for months, and engineered for minimal toxicity. It targets unmet needs in trauma care, organ transplantation preservation, anemia treatment, and ischemic conditions. No clinical results have been reported as the company remains in early development stages[4].

Therapeutic areas: CardiovascularImmunologyHematology
Modalities: Protein-based drugsHemoglobin-based oxygen carriers (HBOC)
Industry: Biotech

Beyond the preview

Go deeper on 20BLOC.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 20BLOC.

Explore the full profile